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Abstract 
Background: The magnitude of participation bias due to non‑participation should be considered for cancer patients 
invited to population‑based surveys. We studied participation rates among persons with and without cancer in a large 
population based study, the Nord‑Trøndelag Health Study (HUNT).
Methods: Citizens 20 years or above living in the Nord‑Trøndelag County of Norway have been invited three times 
to comprehensive health surveys. The invitation files with data on sex, invitation date and participation were linked to 
the Cancer Registry of Norway. In a first step unadjusted crude participation rates (participants/invited persons) were 
estimated for cancer patients (CaPts) and non‑cancer persons (NonCaPers), followed by logistic regression analyses 
with adjustment for age and sex. To evaluate the “practical” significance of the estimated odds ratios in the cancer 
diagnosis group, relative risks were also estimated comparing the observed rates to the estimated rates under the 
counterfactual assumption of no earlier cancer diagnosis among CaPts.
Results: Overall 3 % of the participants in the three HUNT studies were CaPts and 59 % of them had been diagnosed 
with their first life‑time cancer >5 years prior to each survey. In each of the three HUNT surveys crude participa‑
tion rates were similar for CaPts and NonCaPers. Adjusted for sex and age, CaPts’ likelihood to participate in HUNT1 
(1984–86) and HUNT2 (1995–97), but not in HUNT3 (2006–2008), was statistically significantly reduced compared to 
NonCaPers, equaling a relative risk of 0.98 and 0.96, respectively. The lowest odds ratio emerged for CaPts diagnosed 
during the last 2 years preceding a HUNT invitation. Only one‑third of CaPts participating in a survey also participated 
in the subsequent survey compared to approximately two‑thirds of NonCaPers, and 11 % of CaPts participated in all 
three HUNT surveys compared to 37 % of NonCaPers.
Conclusion: In the three HUNT surveys no or only minor participation bias exist as to CaPts’ participation rates. In 
longitudinal studies selection bias as to long‑term cancer survivorship should be taken into account, the percentage 
of repeatedly participating CaPts diminishing more strongly than among NonCaPers.
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Background
Many countries in the Western world have public regis-
tries which cover the entire population or specified sub-
groups reflecting the prevalence and incidence of major 
adverse health conditions like cardiovascular diseases 
or cancer. Population-based surveys based on question-
naires have the potential to provide additional knowledge 
about self-reported physical and psycho-social health in 
large cohorts including information on overall wellbe-
ing and life style. Linked together with data from public 
registries findings from population-based cross-sectional 
or longitudinal surveys provide extended data about the 
health in the general population. Such data may be used 
when national health-related interventions are designed.
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Among other factors the validity of data from pop-
ulation-based surveys depends on the participation 
rate among the invited individuals. Non-participation 
increases the risk of selection bias which easily occurs 
in surveys that are not based on randomly selected 
individuals.
According to the medical literature, non-participation 
in general health surveys is associated with low socio-
economic status (low education, low income, no health 
insurance), reduced general health, and increased post-
survey mortality of the invited individuals [1–9]. The 
participation rates in studies of persons with specific dis-
eases (diabetes mellitus, mental disorders, chronic lung 
diseases, cardiovascular diseases, diabetes mellitus) have 
been analyzed in several reports [5, 6, 8–10] whereas 
comparable rates among person with malignant diseases 
have been published less often. When analyzed, the par-
ticipation rates of persons with cancer seemed to be rela-
tively low [11, 12].
The Nord-Trøndelag Health Studies (Helseun-
dersøkelse i Nord-Trøndelag, HUNT) have collected 
individual population-based data through three surveys: 
HUNT1 (1984–86), HUNT2 (1995–97), and HUNT3 
(2006–08) [13]. Besides recording of basic socio-demo-
graphic data (age, education, civil status), these surveys 
have covered common adverse health conditions. The 
HUNT surveys are considered to be representative of 
the health situation of the total Norwegian population. 
Results of the HUNT surveys have so far resulted in 
approximately 600 peer-reviewed papers in national and 
international journals.
Data from the HUNT studies enable studies of the 
health of cancer patients (CaPts) to matched controls 
without cancer (NonCaPers), all identified among the 
HUNT participants (internal comparisons). Data from 
NonCaPers HUNT-participants have been used as con-
trols when clinical cancer samples are studied (external 
comparisons) [14–16]. However, the participation rates 
of CaPts compared to NonCaPers, factors associated 
with participation and eventual inter-survey differences 
have not been focus of any report so far.
Based on a questionnaire sent to non-participants 
9 months after HUNT3 the percentages of persons with a 
cancer diagnosis did not differ between participants and 
non-participants, with only marginal differences between 
males and females. [9] This result might suggest absence 
of any major selection bias related to participation rates 
among CaPts. However, this study was based on non-par-
ticipants’ self-report and did not characterize the CaPts 
as to age, cancer type or time since diagnosis. Based on 
the unique person number given to all inhabitants who 
live in Norway, there is an opportunity to link all persons 
invited to the HUNT surveys to the Cancer Registry of 
Norway (CRN). Accordingly, all invited CaPts can be 
identified enabling further characterization of the partici-
pating and non-participating CaPts on demographic and 
selected medical variables. These observations an then 
be compared to corresponding results emerging among 
NonCaPers.
On this background the overall aim of our study was to 
describe eventual selection bias and its magnitude in the 
HUNT surveys related to CaPts’ participation. Their par-
ticipation rates were compared to those observed among 
NonCaPers using a cross-sectional design for each of the 
three surveys, followed by a longitudinal analysis which 
addressed the individuals’ participation in subsequent 
surveys.
Methods
Sample recruitment
The current analyses were based on individualized record 
linkage between the three HUNT surveys and the CRN 
based on the unique Norwegian person number used by 
all public and large clinical registries.
The HUNT surveys
All inhabitants aged 20  years and above living in the 
county of Nord-Trøndelag of Norway have been invited 
to participate in three consecutive health surveys [13]. 
In all surveys data were collected by questionnaires and 
clinical examinations addressing several adverse health 
issues [cardiovascular disease, respiratory diseases, can-
cer, mental distress (anxiety, depression), and musculo-
skeletal diseases]. The aims of each survey were described 
in an invitation letter sent to all eligible persons together 
with the first questionnaire (Q1). All invited persons were 
encouraged to attend a subsequent standard examination 
of height, weight, blood pressure, and blood sampling tak-
ing part in their local municipality. Q1 was returned at 
this examination, and the persons were asked to complete 
additional questionnaires. The present study is based on 
data from the returned Q1 questionnaire of each survey.
The Cancer Registry of Norway
The CRN was established in 1951, and since 1953 clini-
cians and pathologists in Norway have been obliged by 
law to submit individualized information about all new 
cancer diagnoses to the CRN. For each patients the CRN 
collects information on demographic variables (sex, age, 
residence), cancer type, date of diagnosis, initial treat-
ment and date and cause of death. The CRN covers 99 % 
of all new cancer diagnoses in persons living in Norway 
[17]. Based on data from the CRN the date of the first-
time malignancy-proving biopsy determines the start of 
a patient’s cancer trajectory. However, 3–8  weeks usu-
ally elapse before the patients are informed about their 
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malignancies, treatment and prognosis categorizing 
them as persons expected to be aware of their malignant 
diagnosis.
 For each person invited to one of the HUNT surveys 
cancer-related information was retrieved from the CRN, 
excluding all records on non-melanoma skin cancer. Due 
to data protection the date of a cancer diagnosis as well 
as the date of death was set to the 15th within the true 
month and year. In cancer patients with multiple malig-
nancies only the first diagnosis was considered.
Definitions and data management
Participants were defined as persons returning the Q1 
questionnaire of each particular HUNT survey. The 
crude participation rates depict the number of Q1-par-
ticipants related to the number of invited persons cal-
culated separately for NonCaPers and CaPts. Due to 
the imprecise day in the date of cancer diagnosis and an 
eventual delayed information to a patient about his/her 
most recent malignant diagnosis, CaPts were regarded as 
NonCaPers if their first-time cancer diagnosis preceded 
the survey invitation date by 2 months or less. The time 
from a cancer diagnosis to a HUNT invitation (“diagnos-
tic interval”) was categorized as: <2 years, 2–5 years and 
>5 years. Participation rates were calculated within each 
of these time categories.
The files extracted from the HUNT surveys for the 
current project contained the dates of survey invitation, 
the persons’ age at invitation (categorized as <50, 50–59, 
60–69, 70–80 and 80+  years), participation status (Yes/
No), and information on date of death or emigration 
from the county. Individuals who had died or emigrated 
prior to the date of invitation were removed before fur-
ther analysis.
Statistics
Descriptive within-group and between-group compari-
sons were performed using non-parametric descriptive 
and analytic methods [median (range), Mann–Whitney 
U test, Chi square test].
With age and sex being independent variables logis-
tic regression analyses were performed separately for 
each survey and the participation rates of NonCaPers 
being the reference. A challenge with the logistic regres-
sion analysis was the interpretation of odds ratios due 
to high proportions of participation. Generally, odds 
ratios are often interpreted as approximated rela-
tive risks, but this approximation is only valid for rare 
events. For frequent events such as participation in the 
HUNT surveys, estimated odds ratios can seem large in 
the absence of substantial differences. Hence, we also 
estimated a corresponding predicted relative risk given 
by the ratio between the observed attendance among 
CaPts and the estimated attendance for the same group 
under the counterfactual assumption of no earlier can-
cer diagnosis. This estimated relative risk can be seen 
as an estimate of the real life differences which could be 
expected from the estimated odds ratios among CaPts. 
An alternative calculation using all the data gave similar 
results.
Statistical significance was defined by p  <  0.05. Anal-
yses were performed using the SPSS version 18 and 
STATA version 13 software packages.
Results
Crude participation rates
The participation rates in HUNT1, HUNT2 and HUNT3 
were 90, 70 and 55 %, respectively with 2, 3 and 5 % of 
the participants being CaPts. In HUNT1 and HUNT2 
the participation rates were similar for CaPers and 
NonCaPers (Table  1). In HUNT3 the participation 
rate of CaPts exceeded that of NonCaPers (58 vs 54  %, 
p < 0.001).
In all three surveys the diagnostic interval exceeded 
5  years for more than 50  % of the CaPts. (median 5.1, 
6.8 and 7.0 years for HUNT1, 2 and 3, respectively). The 
lowest participation rates were observed among CaPts 
diagnosed within 2 years preceding the HUNT invitation 
(Table 1). This participation rate decreased from HUNT1 
to HUNT2 and further to HUNT3. In HUNT3 only 46 % 
of the invited CaPts participated if their diagnosis was 
made during the last 2 years, opposed to 86 % in HUNT1. 
Type of malignancy had limited impact on CaPts’ par-
ticipation. Among the five types of CaPts those with 
lung cancer, the malignancy with the poorest prognosis, 
had the lowest participation rate in each of the HUNT 
surveys.
Sex
In each HUNT survey the participation rates among 
NonCaPers were lower in males compared to females, 
with 11 % difference in HUNT3 (Table 1). Much smaller 
sex differences were observed among participating CaPts, 
and in HUNT3 the participation rates among male CaPts 
even exceeded that of NonCaPers (57 vs. 49 %, p < 0.001).
Age
Participating CaPts were generally 20  years older than 
NonCaPers (Table 1). Non-participating NonCaPers were 
10–15 years younger than attending NonCaPers, whereas 
the comparable difference in CaPts ranged from 4 to 
7  years. In HUNT2 and HUNT3, more CaPts aged less 
than 70  years than comparable NonCaPers participated 
[p < 0.001 for HUNT2 (78 vs. 71 %) and HUNT3 (64 vs. 
54 %)], with opposite findings for individuals 70 years old 
or older (HUNT2: 63 vs 68 %; HUNT3: 51 vs 55 %).
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Age and sex
Within each of the sub-categories of age and separately 
for males and females the participation rates between 
CaPts and NonCaPers were small, none of them exceed-
ing 10  % (Fig.  1). According to the multivariate logistic 
regression analyses (after adjustment for age and sex) 
CaPts were shown to be significantly less likely than Non-
CaPers to participate in HUNT1 and HUNT2, (HUNT1: 
by 20  %; HUNT2: by 13  %), with no such difference 
emerging for HUNT3. However, the practical differ-
ences were minor with estimated corresponding relative 
risks of 0.98 and 0.96 (Table 2). Further analyses proved 
that significantly reduced odds ratios were only observed 
among CaPts from HUNT1 and HUNT2 whose diag-
nostic interval was less than 2 years (reduction by 39 and 
27 % in HUNT1 and HUNT2, respectively) (Table 3).
Longitudinal assessment
Approximately one-third of the CaPts and two-thirds of 
NonCaPers participating in the first of two subsequent 
HUNT surveys also participated in the following HUNT 
survey (HUNT1 and HUNT2 or HUNT2 and HUNT3; 
Table 4). Eleven percent of the CaPts from HUNT1 par-
ticipated in all three HUNT surveys, compared to about 
37 % for individuals without cancer (p < 0.001).
Discussion
After adjustment for age and sex CaPts’ likelihood to 
participate was significantly reduced in HUNT1 and 
HUNT2, but not in HUNT3. However, any differences in 
participation rates were small with the largest differences 
emerging in CaPts diagnosed within the last 2 years prior 
to a HUNT survey invitation. Respectively, one-third 
and approximately 10 % of the CaPts from HUNT1 par-
ticipated in HUNT2 and HUNT3, the comparable figures 
more than tripled for NonCaPers.
During the last decades health survey participation 
rates have generally varied between 60 and 80 %, but have 
declined over time. [8] This trend was also demonstrated 
for all invited persons in the HUNT surveys [13], and 
confirmed for CaPts in the present study. Morton et  al. 
[18] list some factors which may explain the variability 
Table 1 Number of  participants and  participation rates among  persons without  cancer (NonCaPers) and  those with  a 
cancer diagnosis (CaPts)
a Number of all invited persons per HUNT survey (participation rate)
b Participants only
c % participating individuals (among those invited in the indicated category)
d Non-participating NonCaPers: HUNT1: 35 years (20–102); HUNT2: 38 years (20–104); HUNT3: 42 years (20–103)
e Non-participating CaPts: HUNT1: 73 years (22–98); HUNT2: 77 years (20–100); HUNT3: 74 years (20–101)
HUNT1 [n 85,516 (90 %)]a HUNT2 [n 92,406 (70 %)]a HUNT3 [n 93,552 (55 %)]a
NonCaPers CaPts NonCaPers CaPts NonCaPers CaPts
Invited 83,465 2051 89,301 3105 89,188 4364
Participating 75,083 (90 %) 1837 (90 %) 62,899 (70 %) 2171 (70 %) 48,159 (54 %) 2511 (58 %)
Sexb
 Males 36,915 (88 %)c 760 (89 %) 29,557 (66 %) 931 (70 %) 21,822 (49 %) 1167 (57 %)
 Females 38,168 (92 %) 1077 (90 %) 33,342 (75 %) 1240 (69 %) 25,336 (59 %) 1344 (58 %)
Age (years)b
 Median (range) 47 (19–101)d 69 (22–99)e 48 (19–104) 70 (20–95) 53 (19–101) 69 (21–96)
  <70 63,782 (90 %) 1008 (91 %) 53,298 (71 %) 1120 (78 %) 41,216 (54 %) 1396 (64 %)
  ≥70 11,301 (89 %) 829 (87 %) 9601 (68 %) 1051 (63 %) 6943 (55 %) 1115 (51 %)
Years since cancer diagnosisb
 Median (range) 5.1 (0.2–33) 6.8 (0.2–44) 7.0 (0.2–54)
  <2 397 (86 %) 374 (67 %) 441 (46 %)
  2–5 451 (91 %) 479 (68 %) 531 (58 %)
  >5 989 (90 %) 1318 (71 %) 1539 (58 %)
Cancer typeb
 Breast 392 (89 %) 394 (71 %) 501 (60 %)
 Colorectal 245 (89 %) 306 (68 %) 367 (55 %)
 Prostate 184 (88 %) 247 (66 %) 438 (64 %)
 Lung 19 (86 %) 29 (59 %) 48 (49 %)
 Melanoma 102 (90 %) 169 (80 %) 255 (61 %)
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of participation rates: differences in method of contact 
(mail, telephone), use of incentives, mandatory versus 
optional collection of biological material, and variability 
of the disease to be studied. The length and eventual sen-
sitive nature of questionnaires may also be reasons why 
invited persons decline to participate [4], together with 
the opportunity of extensive data linkage. Full time work 
and rural residence have also been discussed as reasons 
for non-participation in general [11].
Analyses of multiple health surveys including the 
HUNT surveys have documented elevated non-
participation rates for identifiable subgroups as 
Fig. 1 Participation rates for persons with or without a previous cancer diagnosis in HUNT1, HUNT2 and HUNT3, separately for men and women, 
according to five age categories
Table 2 Estimated odds ratios for crude participation rates for cancer patients in HUNT surveys: unadjusted and adjusted 
odds ratios for all persons with vs. without previous cancer diagnosis (reference), plus corresponding predicted relative 
risk (for easier interpretation of the adjusted odds ratios)*
*  With overall high participation rates, odd ratios must be interpreted with caution, and they are not good approximations of relative risks. Therefore use of predicted 
relative risks for easier interpretation
**  Relative risks given as the difference between the observed attendance in the cancer diagnosis group and the estimated attendance for the same group under the 
counterfactual assumption of no earlier cancer diagnosis (using multivariate logistic regression adjusting for sex and age). See “Methods” section for details
***  Age and age^2 (quadratic)
Odds ratio* Predicted relative risk**
No cancer  
(reference)
Cancer Cancer
Unadjusted Adjusted for sex
and age***
HUNT1 1.0 0.96 {0.83, 1.11} 0.80 {0.68, 0.92} 0.98
HUNT2 1.0 0.98 {0.90, 1.05} 0.87 {0.80, 0.95} 0.96
HUNT3 1.0 1.15 {1.09, 1.23} 0.96 {0.90, 1.03} 0.98
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socio-economically deprived individuals [1, 2, 6], and for 
those with reduced physical and mental health [3–6, 8, 
9]. Associations with non-participation have been docu-
mented for cardiovascular diseases [9], chronic lung dis-
eases [6, 19], but not for diabetes mellitus [10, 13]. The 
participation rates among males are often lower than 
among females [4, 19, 20] though Jacobsen et al. observed 
the opposite in the Rochester Epidemic Project [21]. In 
the HUNT surveys males, in particular younger men, had 
particularly low participation rates [13]. However, among 
CaPts participating in the HUNT studies the sex differ-
ences were much less, with more male than female CaPts 
participating in HUNT3.
The percentages of participating CaPts seem particu-
larly low in reports if the patients are invited by cancer 
registries without involvement of the institution or the 
medical team responsible for the patients’ treatment. In 
Geller et al.’s study only 33 % of the invited cancer survi-
vors participated [11], this percentage being in agreement 
with that observed by Jegou et  al. [12]. These authors 
identified patients with colorectal cancer in a regional 
cancer registry and invited them to participated in future 
research. Only 37 % of all persons with rectal cancer were 
willing to be included in such a research-based cancer 
registry. This contrasts to the experience of Downing 
et  al. [22] of a participation rate of 63  % among British 
persons with colorectal cancer. These authors included 
the names of the hospital director and of the chair of the 
patient’s responsible medical team in the head of the invi-
tation letter. With this background, participation rates 
of 90  % (HUNT1), 70  % (HUNT2) and 58  % (HUNT3) 
among invited CaPts are surprisingly high. Among sur-
veys specifically inviting CaPts [11, 12] non-awareness of 
the malignant diagnosis may be a reason for non-partic-
ipation. In Nord et al’s [23] analysis of HUNT2, 26 % of 
non-participating CaPts identified by the CRN, claimed 
never to have been diagnosed with cancer.
Our findings support the suggestions by Langhammer 
et al. [9] of no or only minor differences between CaPts 
and NonCaPers as to participation in the HUNT studies, 
even though these authors’ observations were based on 
non-participants’ self-report by a questionnaire sent to 
them 9 months after the original invitation. In contrast, 
our study uses the CRN as basis of diagnostic validation. 
Therefore we are able to present more patient details 
than that study.
In agreement with Ness et  al. [20] we observed the 
influence of the diagnostic interval on CaPts’ participa-
tion rate. In their US survey reduced “participation limi-
tations” were reported among cancer patients whose 
cancer diagnosis preceded the survey for >5  years as 
compared to shorter intervals. In our study the reduced 
participation rates in CaPts with a diagnostic interval of 
<2  years may be explained by particularly poor health 
due to an aggressive malignancy or treatment-related side 
effects. Further, recently diagnosed cancer patients regu-
larly have multiple contacts with the health care services 
during the first 2 post-diagnosis years, and many of them 
have not completed their initial treatment before 2 years 
have elapsed since diagnosis. They probably anticipate 
Table 3 Estimated odds ratios for  crude participation rates for  cancer patients in  HUNT surveys: adjusted odds ratios 
for persons with cancer with varying time since diagnosis compared to persons without cancer diagnosis (reference)*
*  With overall high participation rates, odd ratios must be interpreted with caution and are not good approximations of relative risks
Odds ratio*
No cancer  
(reference)
Cancer
Less than 2 years since  
cancer diagnosis
2–5 years
since cancer diagnosis
5+ years since
cancer diagnosis
HUNT1 1.0 0.61 {0.47, 0.81} 0.91 {0.67, 1.24} 0.85 {0.69, 1.05}
HUNT2 1.0 0.73 {0.61, 0.88} 0.87 {0.73, 1.03} 0.93 {0.83, 1.03}
HUNT3 1.0 0.94 {0.81, 1.09} 0.95 {0.83, 1.09} 0.97 {0.90, 1.05}
Table 4 Repeated participation in the three HUNT surveys
All 
participants
HUNT1
HUNT2
HUNT3
76920
47243
30386
HUNT 1+2+3 27967 36%3
Non-Cancer
Persons
HUNT1
HUNT2
HUN 3
75083
46607
30173
HUNT 1+2+3 27761 37%3
Cancer
Patients
HUNT1
HUNT2
HUNT3
1837
636
213
HUNT 1+2+3 206 11%3
61%1
64%2
62%1
65%2
35%1
33%2
40%1
40%1
12%1
1 Percentage of HUNT1 participants attending HUNT 3
2 Percentage of HUNT2 participants attending HUNT3
3 Percentage of HUNT 1 participants with participation in all three surveys
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few benefits from participation in population-based 
HUNT surveys, and they therefore may be less motivated 
to participate. Researchers using the HUNT studies, 
and probably also other population-based health sur-
veys, should therefore be aware of possible participation 
bias due to short diagnostic interval in cancer patients. 
Any statements comparing CaPers with NonCaPers may 
be less valid for cancer survivors less than 2  years after 
diagnosis.
Large differences in participation rates of CaPts and 
NonCaPers became more evident in the longitudi-
nal assessment of participation. Approximately 60  % 
of the NonCaPers, but only one-third of the CaPts 
participated in two HUNT surveys, the comparable 
differences for attendance in all three surveys being 
respectively 37 and 11  %. The differences in repeated 
participation among persons with or without cancer 
leave comparisons of CaPts and NonCaPers problem-
atic in longitudinal studies which aim to assess cancer 
patients’ health in subsequent surveys. On the other 
hand, the HUNT surveys allow valid analyses of health 
changes in long-term cancer survivors, if investigators 
are aware of the participation bias in the relatively few 
CaPts with repeated participation: Persons with a prior 
cancer diagnosis participating in more than one health 
survey are probably particularly healthy, the majority 
of them being without tumor activity of their first life-
time cancer.
Our study has several limitations. First, the defini-
tion of cancer patients and thus the estimation of their 
participation rates can be debated since patients with a 
first life-time malignant diagnosis within the 2  months 
preceding the date of diagnosis as reported by the CRN 
were not included. The aim of our study was, however, 
to compare participation rates among NonCaPers with 
that of CaPts who were aware of their malignant diag-
nosis. Clinicians know that up to 2  months may elapse 
between performance of a diagnostic biopsy and patient 
information. In our view this justifies the exclusion of 
persons with a first life-time malignant diagnosis within 
2 months from the cohort of CaPts, when participation 
rates were calculated. Retrospectively we could identify 
185 persons who most probably were diagnosed with 
their first life-time cancer within 2  months prior to a 
HUNT invitation (HUNT1 47, HUNT2 61, HUNT3 
77). Of these 105 individuals (57 %) did not participate 
in the relevant HUNT survey. From these figures we 
can stipulate that the non-participation rate for CaPts 
diagnosed within the two preceding would have been 
slightly higher, but without any principal change, if these 
patients had been reported as CaPts. Second, though we 
present results from three population-based studies the 
findings may not be valid for surveys in countries with 
different health care services. In countries without easy 
and non-expensive access to health care services, more 
persons will possibly participate in public health studies, 
than this was the case for the HUNT surveys. Third, we 
have only considered the first life-time cancer in CaPts 
whose records from the CRN could contain up to five 
malignant diagnoses. If the last date of cancer diagno-
sis had been taken into account, the participation rates 
within the diagnostic intervals of less than 5 years would 
have increased. Finally, adjustment for socio-economic 
status would have been desirable, but this informa-
tion was not available during the performance of the 
analyses. The individualized data linkage with Norway’s 
populations-based registries is viewed as an essential 
advantage.
Conclusion
We conclude that participation rates in each of the three 
HUNT surveys vary by sex and age, but that there are 
only minor differences between CaPts and NonCaPers. 
Differences are small and can probably be neglected in 
cross-sectional studies, though researchers should be 
aware of the particularly low participation of CaPts diag-
nosed less than 2  years prior to a HUNT invitation. In 
longitudinal analyses of the HUNT studies participation 
rates diminishes more rapidly among CaPts than among 
NonCaPts, leading to a risk of participation bias favoring 
surviving tumor-free CaPts.
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